Service d'orthopédie, CHU Pontchaillou, 2, rue Le Guilloux, 35033 Rennes, France.
Service d'orthopédie, centre hospitalier Nord-Mayenne, 229, boulevard Paul-Lintier, 53100 Mayenne, France.
Orthop Traumatol Surg Res. 2018 Sep;104(5):695-700. doi: 10.1016/j.otsr.2018.05.008. Epub 2018 Jun 20.
Osteochondral defects due to advanced osteochondritis of the knee eventually cause osteoarthritis. Autologous matrix-induced chondrogenesis (AMIC) may hold potential for overcoming the treatment challenges raised by defects larger than 2cm. The primary objective of this study was to assess medium-term functional outcomes of AMIC. The secondary objective was to confirm the absence of adverse events.
AMIC significantly improves knee function in patients with osteochondritis responsible for osteochondral defects grade III or IV in the International Cartilage Repair Society (ICRS) classification.
A total of 13 consecutive patients managed using AMIC between September 2011 and November 2016 were included in a prospective, single-centre, single-surgeon study. There were 8 males and 5 females with a mean age of 29 years (range, 15-51 years). Among them, 9 had had previous surgery. The ICRS grade was IV in 12 patients and III in 1 patient. The defects had a mean surface area of 3.7cm (range, 2.2-6.9cm) and mean depth of 0.5mm (range, 0.4-0.8). In each patient, knee function was assessed by an independent examiner based on validated instruments (Knee injury and Osteoarthritis Outcome Score [KOOS], subjective International Knee Documentation Committee [IKDC] score, and visual analogue scale [VAS] pain score).
After a median follow-up of 24 months (range, 12-42 months; minimum, 1 year), 11 patients had significant improvements, with mean increases in the IKDC score and KOOS of 27 and 28 points, respectively. The scores remained stable after the first year. Of the 2 patients with poorer outcomes, 1 had a history of multiple surgical procedures and the other was a 51-year-old female with a defect surface area of 6.9cm. No post-operative complications were recorded.
AMIC is a reliable single-stage method that is both reproducible and widely available. AMIC significantly improves knee function scores in patients with large osteochondral defects due to advanced osteochondritis of the knee.
IV, prospective cohort study.
膝关节进展性骨软骨炎导致的骨软骨缺损最终会引发骨关节炎。自体基质诱导软骨生成术(AMIC)可能有潜力克服大于 2cm 的缺损带来的治疗挑战。本研究的主要目的是评估 AMIC 的中期功能结果。次要目的是确认无不良事件发生。
在国际软骨修复学会(ICRS)分类中,AMIC 可显著改善因膝关节进展性骨软骨炎导致的 III 或 IV 级骨软骨缺损患者的膝关节功能。
2011 年 9 月至 2016 年 11 月,我们对 13 例连续采用 AMIC 治疗的患者进行了前瞻性、单中心、单术者研究。8 例为男性,5 例为女性,平均年龄 29 岁(15-51 岁)。其中 9 例有既往手术史。12 例患者 ICRS 分级为 IV 级,1 例为 III 级。缺损的平均表面积为 3.7cm(2.2-6.9cm),平均深度为 0.5mm(0.4-0.8mm)。在每位患者中,由独立的检查者根据已验证的工具(膝关节损伤和骨关节炎结果评分[KOOS]、主观国际膝关节文献委员会[IKDC]评分和视觉模拟评分[VAS]疼痛评分)评估膝关节功能。
中位随访 24 个月(12-42 个月;最短 1 年)后,11 例患者有显著改善,IKDC 评分和 KOOS 评分分别平均增加 27 分和 28 分。第一年过后,评分保持稳定。2 例患者的预后较差,其中 1 例有多次手术史,另 1 例为 51 岁女性,缺损表面积为 6.9cm。无术后并发症记录。
AMIC 是一种可靠的、可重复的、广泛应用的单一阶段方法。AMIC 可显著改善因膝关节进展性骨软骨炎导致的大骨软骨缺损患者的膝关节功能评分。
IV,前瞻性队列研究。